On September 2, 2022 Convert Pharmaceuticals reported that the Clinical Trial Application prepared for the Phase 1 Clinical Trial of CP-506 (NCT04954599) has been approved by both the Competent Authorities and the reference Ethical Committee in the Netherlands (Press release, Convert Pharmaceuticals, SEP 2, 2022, View Source [SID1234618932]). The prodrug will be tested in monotherapy setting as well as in combination with standard treatments such as immune checkpoint inhibitors or chemotherapy. Patient selection will be based upon key biomarkers.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The company now expects to finalise the same procedures in Belgium in the coming months and launch patient recruitment by the end of 2022.